Alto Neuroscience(US:ANRO) Globenewswireยท2025-09-19 13:50Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Alto Neuroscience, Inc. about the lead plaintiff deadline for a class action lawsuit related to the company's initial public offering and subsequent securities purchases [1]. Group 1: Class Action Details - Investors who purchased Alto securities between February 2, 2024, and October 22, 2024, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by September 19, 2025 [3]. - The lawsuit claims that throughout the class period, defendants made materially false and misleading statements regarding Alto's business and prospects, particularly concerning the effectiveness of ALTO-100 in treating major depressive disorder [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been ranked No. 1 for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in handling such cases [4].